Tidal Investments LLC Sells 9,099 Shares of Lantheus Holdings, Inc. $LNTH

Posted by on Sep 16th, 2026

Tidal Investments LLC decreased its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH – Free Report) by 28.8% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 22,466 shares of the medical equipment provider’s stock after selling 9,099 shares during the period. Tidal Investments LLC’s holdings in Lantheus were worth $2,492,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of LNTH. Jupiter Topco LLC acquired a new position in shares of Lantheus in the 2nd quarter worth approximately $575,628,000. Norges Bank acquired a new stake in Lantheus during the 4th quarter valued at $76,197,000. Assenagon Asset Management S.A. increased its holdings in Lantheus by 440.3% during the 2nd quarter. Assenagon Asset Management S.A. now owns 714,980 shares of the medical equipment provider’s stock valued at $79,320,000 after purchasing an additional 582,661 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund raised its position in Lantheus by 686.1% in the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 598,857 shares of the medical equipment provider’s stock valued at $45,423,000 after purchasing an additional 522,678 shares during the last quarter. Finally, Summit Street Capital Management LLC bought a new position in Lantheus in the 2nd quarter valued at $44,454,000. Institutional investors own 99.06% of the company’s stock.

Lantheus Stock Performance

Lantheus stock opened at $100.73 on Wednesday. The company has a market cap of $6.57 billion, a PE ratio of 24.33 and a beta of -0.03. The company has a current ratio of 3.06, a quick ratio of 2.89 and a debt-to-equity ratio of 0.43. Lantheus Holdings, Inc. has a 1 year low of $49.67 and a 1 year high of $111.86. The company’s 50-day moving average is $102.08 and its two-hundred day moving average is $94.24.

Lantheus (NASDAQ:LNTH – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The medical equipment provider reported $1.55 EPS for the quarter, topping the consensus estimate of $1.30 by $0.25. The company had revenue of $388.18 million during the quarter, compared to analysts’ expectations of $363.23 million. Lantheus had a net margin of 17.69% and a return on equity of 28.10%. Lantheus’s revenue was up 2.7% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.57 EPS. Equities analysts anticipate that Lantheus Holdings, Inc. will post 4.5 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on LNTH. Mizuho lowered their target price on Lantheus from $120.00 to $115.00 and set an “outperform” rating for the company in a research note on Wednesday, July 29th. Weiss Ratings downgraded shares of Lantheus from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday, September 10th. TD Cowen lowered shares of Lantheus from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $110.00 to $102.50 in a report on Monday, August 3rd. William Blair set a $102.50 price objective on shares of Lantheus in a research report on Monday, August 3rd. Finally, Brookline Capital Markets cut shares of Lantheus from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 28th. Four equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $108.11.

Get Our Latest Analysis on Lantheus

Lantheus Company Profile

(Free Report)

Lantheus Holdings, Inc (NASDAQ: LNTH) is a healthcare company that develops, manufactures and commercializes diagnostic imaging agents and radiopharmaceuticals. Its products are designed to help physicians detect, characterize and monitor disease, with applications in cardiology, oncology and other areas of medicine.

The company’s principal products include DEFINITY, an ultrasound-enhancing agent used to improve cardiac ultrasound images, and PYLARIFY, a prostate-specific membrane antigen (PSMA) PET imaging agent used to help identify and assess prostate cancer.

Read More

Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings, Inc. (NASDAQ:LNTH – Free Report).

Institutional Ownership by Quarter for Lantheus (NASDAQ:LNTH)

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.